Genfit
Abierto
SectorSanidad
13.56 5.61
Resumen
Variación precio
24h
Mínimo
12.78
Máximo
13.58
Ingresos | -76M |
|---|---|
Ventas | 32M |
BPA | -1.525 |
Margen de beneficios | -237.939 |
Empleados | 161 |
EBITDA | -7M |
Próximas Ganancias | 29 sept 2026 |
|---|
Capitalización Mercado | 666M |
|---|---|
Apertura anterior | 7.95 |
Cierre anterior | 13.56 |
Noticias sobre sentimiento de mercado
By Acuity
17%
83%
42 / 342 Clasificación en Healthcare
Genfit Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Genfit previsión
Sentimiento
By Acuity
42 / 342 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Genfit
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.